Adverse events290

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

41 to 60 of 290

Type	Event	Organ system	Group	Affected	At risk
other	Administration site swelling	General disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	4	30
other	Administration site swelling	General disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	5	30
other	Administration site swelling	General disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	7	30
other	Administration site swelling	General disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	94	1,162
other	Administration site swelling	General disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	24	1,161
other	Chills	General disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	3	30
other	Chills	General disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	5	30
other	Chills	General disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	1	30
other	Chills	General disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	139	1,162
other	Chills	General disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	119	1,161
other	Injection site bruising	General disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	5	30
other	Injection site bruising	General disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	10	30
other	Injection site bruising	General disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	13	30
other	Injection site bruising	General disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	31	1,162
other	Injection site bruising	General disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	26	1,161
other	Injection site pruritus	General disorders	Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	1	30
other	Injection site pruritus	General disorders	Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections	1	30
other	Injection site pruritus	General disorders	Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections	2	30
other	Injection site pruritus	General disorders	Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections	12	1,162
other	Injection site pruritus	General disorders	Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections	3	1,161

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=3

API reference For AI assistants